1960. Antibiotic Challenge Dose Testing Improves Patient Care and Lowers Costs in a Community Hospital: a Two-year Prospective Study
Session: Poster Abstract Session: Clinical Trials
Saturday, October 6, 2018
Room: S Poster Hall
  • IDSA Poster FINAL 2018.pdf (3.2 MB)
  • Background:

    Penicillin allergy is reported in 10% patients in the U.S. Patients with penicillin allergies are treated with broader spectrum antibiotics, often leading to more antibiotic-resistant infections, including C. difficile, increased risk of surgical site infections, and increased health care costs.


    After informed consent, Medical-Surgical patients with documented allergies to penicillin (P) or cephalosporins (C) were given challenge doses through a standardized 2-step protocol from June 2015 to November 2017 at our community hospital. Patients with documented IgE-mediated hypersensitivity (HSR), rash or unknown reactions were eligible. Those with anaphylaxis or Type II-IV HSR were excluded. Treating clinicians selected the antibiotic for testing guided by the protocol: 323/336 patients (96%) were challenged with C. Based on results, allergies were updated in patients’ charts, noting that tolerance of cephalosporins does not preclude penicillin allergy. Charts were reviewed to determine adverse events and antibiotic narrowing, the latter adjudicated by ID specialists not directly involved in the patient’s care. A cost analysis used the acquisition cost of administered antibiotics before and after testing.


    336 patients (53 Medical, 283 Surgical) underwent the allergy test dose protocol: 267 with reported P allergy, 47 C allergy, 22 P+C allergy. None had a major adverse reaction. 7 patients (2%) experienced minor reactions: rash (4), throat irritation (1), urticaria (1), wheezing (1). Before testing, 321/336 were prescribed inappropriate or broad antibiotics. After challenge dose testing, the antibiotic spectrum was narrowed in 308/321 (96%). The total Pharmacy cost savings was $38,281.00 with the optimized antibiotic regimen, translating to $630 saved per patient. In Surgical patients there was a 50% cost savings.


    Despite the frequency with which beta-lactam allergies are reported, few patients had an allergy that interfered with optimal treatment when tested. This standardized protocol can be safely performed in a community hospital setting and lead to improved antibiotic choice and pharmacy cost savings.

    Ref: Iammateo M et al, J Allergy Clin Immunol Pract , Nov. 2014; 2, 768-74

    Barbara Lambl, MD MPH1, Samira Reyes-Dassum, MD2, Vinit Oommen, MD3, Oluchi Dike, MD2, Monique Freeley, RPh4, Darci Finocchiaro, MD5, Japheth Mukaya, MD6, AnaMaria Bensaci, MD MPH2, Johanna O'Connor, MD7 and Kimberly G. Blumenthal, MD, MSc8, (1)Infectious Diseases/Internal Medicine, North Shore Medical Center, Salem, MA, (2)Medicine, North Shore Medical Center, Salem, MA, (3)Medicine, 81 Highland Ave, Salem, MA, (4)Pharmacy, North Shore Medical Center, Salem, MA, (5)Primary Care, Lahey Health, Beverly, MA, (6)Gastroenterology, Univ. Massachusetts Memorial Medical Center, Worcester, MA, (7)Anesthesia, North Shore Medical Center, Salem, MA, (8)Edward P. Lawrence Center for Quality and Safety, Massachusetts General Hospital, Boston, MA


    B. Lambl, None

    S. Reyes-Dassum, None

    V. Oommen, None

    O. Dike, None

    M. Freeley, None

    D. Finocchiaro, None

    J. Mukaya, None

    A. Bensaci, None

    J. O'Connor, None

    K. G. Blumenthal, None

    See more of: Clinical Trials
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.